Department of Health and Human Services (HHS)
HHS Secretary Tom Price offered some optimism about a vaccine for addiction, but experts say such it's far from reality.
The feds are eyeing top pharmas for patient assistance funding—and with one settlement in the works, those players should be scrambling.
Beleaguered Insys faces yet another legal challenge with Anthem's decision to take the opioid drugmaker to court.
After fears that President Trump may push for a change in vaccine policy, Fitzgerald's appointment will likely be a relief to medical professionals.
The U.S. Attorney’s Office for the District of Massachusetts isn’t the only one investigating Alexion over its support of organizations that help Medicare patients.
The Trump administration is reiterating its ambitions to lower drug costs, but some in Congress aren't buying it.
Mylan agreed to pay $465M to settle a federal probe into underpaid Medicaid rebates, but that's less than half the cost to taxpayers, HHS says.
The U.S. could run into a vaccine supply predicament if an influenza pandemic hits, since only one drugmaker has a domestic facility with egg-based vaccine production capabilities.
Drug importation will get another try in Congress. Pricing crusader Sen. Bernie Sanders and other lawmakers rolled out new legislation on Tuesday, pushing the tactic as one solution to pharma sticker shock.
The drug industry has built a unified wall of resistance to a pricing and transparency push in Maryland, the latest fight over state action against pricey meds.